Login to Your Account

Sopherion's Myocet Licensing Inspires $47M Series B Round

By Randall Osborne

Friday, September 24, 2004
Sopherion Therapeutics Inc. raised $47 million in a Series B venture financing and, at the same time, entered a licensing deal with Zeneus Pharma Ltd. for Myocet, a breast cancer therapy approved in Europe and Canada. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription